Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score

Atsushi Nanashima, Junichi Masuda, Satoshi Miuma, Yorihisa Sumida, Takashi Nonaka, Kenji Tanaka, Shigekazu Hidaka, Terumitsu Sawai, Takeshi Nagayasu

Abstract

AIM: To compare the prognosis of patients who underwent hepatectomy and ablation using the modified Japan Integrated Staging score (mJIS).

METHODS: We examined the clinicopathologic records and patient outcomes in 278 HCC patients including 226 undergoing hepatectomy and 52 undergoing ablation therapy.

RESULTS: Cirrhosis was more frequent in the ablation group. Tumor size, number and presence of vascular invasion were significantly higher in the operation group compared to the ablation group. The local recurrence rate adjacent to treated lesions was significantly higher in the ablation group compared to the operation group (P < 0.05). The 3- and 5-year survival rates in the ablation and the operation group were 66% and 78%, and 50% and 63%, respectively, but not significantly different. Over 50% survival rates were observed in patients with a mJIS score of 0-2 in both groups. However, survival rates with a score of 3-5 in both groups were significantly lower.

CONCLUSION: According to the mJIS system, both local treatments could be selected for patients with a score of 0-2. However, for patients with a score more than 3, liver transplantation might be a better option in patients with HCC.

© 2008 WJG. All rights reserved.

Key words: Hepatocellular carcinoma; Hepatectomy, Ablation; Modified Japan integrated staging score; Liver transplantation

http://dx.doi.org/10.3748/wjg.14.58

INTRODUCTION

Although hepatic resection is supposed to be the best curative local treatment for hepatocellular carcinoma (HCC), sufficient hepatic functional reserve is necessary. In recent years, various treatment modalities have become available for HCC patients and the appropriate treatment should be selected according to tumor staging and liver function. In the past decade, combined staging systems with tumor factors and liver function in HCC patients have been proposed worldwide. We also proposed the modified cancer of the liver Italian program (mCLIP) score and the modified Japan Integrated Staging score (mJIS). Comparing the various staging systems using multivariate survival analysis, mJIS is the best available system to predict survival in HCC patients after hepatectomy. The Liver Cancer Study Group of Japan subsequently showed that the mJIS system had good predictive accuracy for survival of Japanese patients with HCC by the records of 42,269 patients diagnosed with HCC registered between 1992 and 1999 in a nationwide Japanese database.

Liver transplantation (LT) has recently been considered a good option to cure some HCC patients with poor hepatic function, such as Child-Pugh C cirrhosis. The usefulness of cadaveric liver transplantation (LT) for HCC treatment has been clarified in Western countries and, furthermore,
Todo et al. reported good results in HCC treatment with the living related LT in Japan[14]. Therefore, LT seems to be a better treatment option in some patients who undergo local treatments in Japan. At this stage, Milan or University of California, San Francisco (UCSF) criteria using tumor factors and the Barcelona Clinic Liver Cancer (BCLC) system using tumor, liver function and performance status, have been used to decide the indication of LT[14,15,16]. It has not yet been clarified whether the mJIS system could be useful in the selection of LT in HCC patients.

In this study, we compare patient demographics, preoperative liver function, tumor parameters and long-term patient survival prognosis of 278 HCC patients who underwent hepatectomy and ablation using mJIS at several cancer institutions in Nagasaki prefecture, Japan. We then discuss the selection of treatment by comparing results by LT. Our aim is to clarify the treatment selection criteria for HCC patients using mJIS.

### MATERIALS AND METHODS

#### Patients

We analyzed 278 patients with HCC who underwent surgical resection or ablation treatments in the Division of Surgical Oncology and the First and Second Department of Internal Medicine, Nagasaki University Graduate School of Biomedical Sciences (NUGSBS), and its related hospitals between 1994 and 2005. The study design was approved by the Human Ethics Review Board of our institution. Informed consent for data collection was obtained from each patient during this period. Anesthetic and patient data were retrieved from the NUGSBS database. Tumor stage and curability were determined according to the Classification of Primary Liver Cancer[17]. Subjects were divided into two groups: (1) Operation group with 226 patients. Preoperative treatment was performed in 78 patients including chemoembolization in 69 and thermal ablation in nine. Operative procedures included hemihepatectomy in 56 patients, anatomical sectriectomy in 74 and partial resection in 96. (2) Ablation group with 52 patients, including alcohol injection in 15 patients, radio-frequency ablation (RFA) in 32, and microwave coagulation therapy (MCT) in five patients.

#### Treatment indications, procedures and follow-up

The volume of liver to be resected was estimated according to results of the indocyanine green retention rate at 15 min (ICG R15) using Takasaki’s formula[18]. Furthermore, hepatic function for hepatectomy was limited as ICGR15 < 40%, Child-Pugh classification A or B, and total bilirubin level < 2 mg/dL according to Miyagawa’s criteria[19]. The expected liver volume for resection, excluding the tumor (cm³), was measured by computed tomography (CT) volumetry[20]. Radical hepatectomy was performed to remove the hepatic tumor without leaving any residual tumor. The indications for hepatic resection of the size and the number of HCC were more than 2 cm, and less than or equal to three lesions, respectively. Distant metastasis was an extra indication for hepatectomy. The assessment of tumor factors in the operation group was confirmed by histopathological examination of the resected specimen. We used the histopathological factors and curability by hepatectomy of the Liver Cancer Study Group of Japan by the Classification of Primary Liver Cancer[17].

For RFA or MCT, the indication for hepatic resection of the size and the number of HCC were less than 3 cm, and less than or equal to three lesions, respectively[21]. Hepatic function for ablations is limited as Child-Pugh classification A or B, platelet counts more than 50000/mm³, prothrombin activity more than 50% and total bilirubin level less than 3 mg/dL. When the appropriate coagulation was estimated to be incomplete by percutaneous puncture, ablations under laparoscopy, thoracoscopy or laparotomy were selected[22,23]. Evaluation of vascular involvement was performed by image analysis, such as enhanced computed tomography or magnetic resonance imaging.

After discharge from hospital, the patient status, laboratory data, and disease recurrence were checked every two to three months.

#### Staging criteria of the modified Japan Integrated Staging score (mJIS)

The assessment of each factor was confirmed by histopathological examination of the resected specimen, or by computed tomography scan, ultrasonography, magnetic resonance image or angiography. We used the pathological tumor-node-metastasis (pTNM) classification system of the Liver Cancer Study Group (LCSG) of Japan in 2000[17]. T category is determined by three factors of number, size and vascular or bile duct invasion. N category is the presence of lymph node metastasis and M category is the presence of distant metastasis.

| T category | Stage I | Stage II | Stage III | Stage IV-A | Stage IV-B |
|------------|---------|----------|-----------|------------|-----------|
| T1         | T1 N0 M0 | T2 N0 M0 | T3 N0 M0 | T4 N0 M0 or T1-T4, N1M0 | T1-4, N0 or I, M1 |

TNM staging has four stages according to T, N and M categories (Table 1A). Classification of Child-Pugh[24] and liver damage grade by LCSG[17] are shown in Table 1B. The original JIS score proposed by Kudo et al comprised the sum of points for two variables of the Japanese TNM classification and Child-Pugh classification[17]. In the modified JIS score proposed by our institute[20,16], the Child-Pugh classification score was replaced by that of liver damage grade by the LCSG of Japan (Table 1C).
Statistical analysis

Continuous data were expressed as the mean ± SD. Data from different groups were compared using one-way analysis of variance (ANOVA) and examined by student’s t-test or Dunnet’s multiple comparison test. For univariate analysis, categorical data were analyzed by the Fisher’s exact test. Disease-free and overall survival rates were calculated according to the Kaplan-Meier method, and differences between groups were tested for significance using the log-rank test. Multivariate analysis was performed using the proportional hazards regression model. A two-tailed P value of < 0.05 was considered significant. Statistical analyses were performed using SAS software (Statistical Analysis System Inc., Cary, NC).

RESULTS

Patient age, gender and period of treatment were not significantly different between groups (Table 2). Rates of cirrhosis and Child-Pugh B were significantly higher in the ablation group. Thirty-five percent of patients underwent pretreatment in the operation group; however, no patients underwent other treatments in the ablation group. Tumor size in the operation group was significantly larger than that in the ablation group. The number of tumors and rate of vascular involvement were significantly higher in the operation group compared to the ablation group. Posttreatment adjuvant treatments were similarly performed in both groups.

In the ablation group, tumor relapse was observed in 22 patients (42%) including 10 with intrahepatic metastasis and 12 with local recurrence adjacent to the ablated site (Figure 1). On the other hand, in the operation group, tumor relapse was observed in 122 patients (62%), which included 117 with intrahepatic metastasis and five with local recurrence adjacent to the resected margin. The local recurrence rate adjacent to the treated lesion was significantly higher in the ablation group compared to the operation group (P < 0.05).

By applying mJIS, discrimination of survival in each score was remarkable (Figure 2). The 3- and 5-year survival rates in the ablation and operation group were 66% and 78%, and 50% and 63%, respectively (Figure 3); however, there were no significant differences between groups. Child-Pugh B was significantly associated with poor disease-free and overall survival (Table 3). Multiple tumors were associated with overall survival. However, difference of treatment modality was not associated with prognosis in the present study. Table 4 shows 3-year survival rates in each score of mJIS; however, there were no significant differences between groups.

Table 1B Definition and criteria of Child-Pugh classification and liver damage grade

| Child-Pugh classification [9] | A | B | C |
|------------------------------|---|---|---|
| Encephalopathy               | none | mild | coma |
| Ascites                      | none | responsive | unresponsive |
| Serum bilirubin (mg/dL)      | < 2.0 | 2.0-3.0 | > 3.0 |
| Serum albumin (g/dL)         | > 3.5 | 2.8-3.5 | < 2.8 |
| Prothrombin activity (%)     | > 70 | 40-70 | < 40 |
| Liver damage grade [5]       | A | B | C |
| Ascites                      | none | responsive | unresponsive |
| Serum bilirubin (mg/dL)      | < 2.0 | 2.0-3.0 | > 3.0 |
| Serum albumin (g/dL)         | > 3.5 | 3.0-3.5 | < 3.0 |
| ICG R15 (%)                  | < 15 | 15-40 | > 40 |
| Prothrombin activity (%)     | > 80 | 50-80 | < 50 |

Table 2 Patient demographics between two groups in HCC patients

| Operation (n = 226) | Ablation (n = 52) | P-value |
|---------------------|-------------------|---------|
| Age (yr)            | 60.2 ± 10.5       | 58.3 ± 10.7 | 0.074 |
| Gender              |                   |          |
| male/female         | 179/43            | 37/15    | 0.283 |
| Time to treatment (yr) | (5.1, 8.4, 11.2) | (5.4, 9.3, 11.6) | 0.28 |
| Background liver    |                   |          |
| chronic hepatitis/cirrhosis/normal | 119/94/13 | 4/48/0 | < 0.001 |
| Hepatitis virus     |                   |          |
| B/C/B&C/non-B/non-C | 72/116/11/27 | 11/36/5/0 | 0.007 |
| Child-Pugh classification |       |          |
| A/B                 | 201/25            | 34/18    | < 0.001 |
| Pretreatment        |                   |          |
| Yes/No              | 78/148            | 0/52     | < 0.001 |
| Tumor size          |                   |          |
| < 5 cm/≥ 5 cm       | 160/66            | 49/3     | < 0.001 |
| Number of tumors    |                   |          |
| solitary/multiple   | 174/52            | 37/15    | 0.479 |
| Vascular involvement|                   |          |
| No/Yes              | 162/64            | 48/4     | 0.003 |
| Adjuvant therapy    |                   |          |
| Yes/No              | 5/221             | 0/52     | 0.615 |

Table 1C Definition and criteria of the JIS and the mJIS

| Score | 0 | 1 | 2 | 3 |
|-------|---|---|---|---|
| Original JIS score [6] | | | | |
| Japanese TNM stage | I | II | III | IV |
| Child-Pugh Classification | A | B | C |
| Modified JIS score [7] | | | | |
| Japanese TNM stage | I | II | III | IV |
| Liver damage grade | A | B | C |

Figure 1 Tumor relapse and site of recurrence after treatment in two groups. Open square shows intrahepatic metastasis and closed square shows the local recurrence adjacent to treated lesion.
DISCUSSION

With recent advances in the ablation technique, local tumor control has improved. In comparison with alcohol injection, the modality option or patient survivals have been remarkably improved in the era of RFA or MCT. Alcohol injection is not recommended at present. In the present study, the ablation group included patients undergoing alcohol injection; however, local control was relatively good because of the small HCC in our series. Some investigators reported that the complete ablation rate is around 90% with HCC and less than 5 mm. Some investigators reported that the complete ablation rate is around 90% with HCC and less than 5 mm. However, Shiina et al described the superiority of RFA compared to hepatectomy. Therefore, superiority or selection criteria between both treatments were preferably performed in one-third of all patients. In these patients, ablation therapy was included as well. Based on these results, the background in both groups was remarkably different, which was also the case in Wakai's report [31].

The pattern of tumor relapse was different in the present study and local recurrence adjacent to the ablated section was significantly higher regardless of careful ablations with a sufficient ablation margin more than 5 mm. Some investigators reported that the complete ablation rate is around 90% with HCC and less than 5 cm could be treated. However, local recurrence in patients undergoing thermal ablation therapy ranged between 9.2% and 13.6%. Hong et al reported that the local recurrence rate in ablation therapy was higher than that in hepatic resection. Therefore, local control by hepatectomy is superior to that by thermal ablation at this stage, based on the above reports and our results. Although the rate of distant liver metastasis might not be remarkably different based on previous reports, tumor recurrence in the distant liver was still high in the operation group in the present study, which might be related.

Table 3 Survival between two groups in HCC patients by multivariate analysis

|                          | Disease-free survival | Overall survival |
|--------------------------|-----------------------|------------------|
|                          | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Child-Pugh classification |           |         |           |         |
| B vs A                   | 2.05 (1.25-3.35) | 0.004   | 2.46 (1.38-4.41) | 0.002  |
| Tumor size               |           |         |           |         |
| ≥ 5 cm vs < 5 cm         | 1.26 (0.83-1.92) | 0.282   | 1.30 (0.75-2.25) | 0.350  |
| Macroscopic findings     |           |         |           |         |
| Confluent type vs Simple nodule type | 1.10 (0.75-1.61) | 0.626   | 1.58 (0.92-2.72) | 0.098  |
| Number of tumor          |           |         |           |         |
| Multiple vs Solitary     | 1.23 (0.82-1.85) | 0.306   | 1.73 (1.03-2.91) | 0.037  |
| Vascular involvement     |           |         |           |         |
| Yes vs No                | 1.24 (0.68-2.27) | 0.481   | 1.76 (0.93-3.31) | 0.080  |
| Alpha-feto protein level |           |         |           |         |
| ≥ 400 ng/mL vs < 400 ng/mL | 1.41 (0.93-2.11) | 0.103   | 1.36 (0.81-2.82) | 0.250  |
| Treatment modality       |           |         |           |         |
| Ablation vs Hepatectomy  | 0.75 (0.46-1.22) | 0.239   | 0.64 (0.39-1.34) | 0.334  |

Table 4 The 3-year survival rates in each score of mJIS after treatments in HCC patients

|                                      | Operation group (n = 226) (%) | Ablation group (n = 52) (%) |
|--------------------------------------|-------------------------------|----------------------------|
| mJIS 0                               | 96                            | 98                         |
| mJIS 1                               | 80                            | 73                         |
| mJIS 2                               | 66                            | 70                         |
| mJIS 3                               | 39                            | 48                         |
| mJIS 4                               | 35                            | 28                         |
| mJIS 5                               | 25                            | -                          |
associated with the advanced stage of HCC as shown in the results.

With respect to patient survival after treatment, superiority between both groups was not clarified, in addition to survival rate, in our results. We applied the mJIS system in this study, which is the best available to predict HCC patient survival after curable treatments[9,11]. By applying this system, survival in each score in the present series was well discriminated. At this stage, indication of treatment modality in HCC patients with early tumor stage and Child-Pugh A or B between hepatectomy and thermal ablation has been controversial[31,32,34,37]. In patients with small HCC less than 2 cm or in patients with impaired liver function such as a Child-Pugh B, survival benefit was similar between both groups[31,34,37]. As described above, local recurrence rate by thermal ablation was higher compared to that by hepatectomy; however, overall survival was not significantly difficult by previous reports[36-38,34-37]. The guideline for diagnosis and treatment in HCC patients was first proposed by Makuuchi et al[39]; however, ablation and hepatectomy were at similar locations in HCC patients with less than four sites and good liver function. Our results showed that the overall survival was similar between both groups, which also had similar mJIS scores, although the included tumor factor and liver function were different between groups, as shown in patient demographics. By multivariate analysis, the difference of treatment modality was not observed in the present study. Up to mJIS score 2, the 3-year survival rate was well maintained; however, survival rate over mJIS score 3 was significantly decreased in both groups. We considered that this border between a score of 2 and 3 might be important to decide the limitation of both conventional treatments. The ultimate curable option should be a liver transplantation. Todo et al reported posttransplant survival in HCC patients who met Milan criteria undergoing living-related liver transplantation in Japan[40]. The 3-year survival rates with or without Milan criteria was 79% and 60%, respectively. This report was a satisfactory result at this stage. Compared to this result, even in a group with Milan criteria not met, survival rates over score 3 in both groups were lower than those in HCC patients undergoing living-related LT. In HCC patients with mJIS score 3-5, patients without remarkable vascular involvement would be included in the indication of liver transplantation. By comparing the survival benefit, transplantation is strongly recommended to improve patient prognosis. In patients with score 0-2, the definition of treatment criteria between groups seemed to be difficult on the present evidence and consensus[39,40]. A study with a large series in Japan will clarify this problem in the near future. Our results did not show superiority or definite indication between both treatment modalities in the present study. To improve the survival results in HCC patients, a combination of both treatments[41], chemoembolization[40], or intra-operative ablation under laparoscopy or laparotomy should be used[42,43].

In conclusion, hepatectomy tended to be selected in patients with better functional liver reserve and, hence, ablation therapy tended to be selected in patients with poor hepatic function in our series. In the ablation group, local recurrence near the treatment region tended to be more than that in the hepatectomy group. By multivariate analysis, macroscopic finding and vascular invasion were significant risk factors, but treatment modality was not a prognostic factor. According to the mJIS system, both treatments could be selected for patients with score 0-2; however, for patients with score more than 3, liver transplantation might be a better option compared to conventional local treatments.

REFERENCES

1 Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S. Hepatic resection for hepatocellular carcinoma -- Japanese experience. Hepatogastroenterology 1998; 45 Suppl 3: 1267-1274
2 Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiri M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229
3 Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-1619
4 Cillo U, Vitale A, Grigoletto F, Farinatti F, Brolese A, Zanus G, Neri D, Bocogni P, Srsen N, D'Amico F, Ciarleglio FA, Bridda A, D'Amico DF. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-731
5 The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755
6 Kudo M, Chung H, Osaki Y, Kojiri M, Makuuchi M, Nakagawa T, Nakagawa Y, Sato Y, Takayama T, Kubota K, Nakagawa Y, Kato A, Inoue K, Kobayashi K, Kojiri M, Makuuchi M, Nakamura Y, Okita K, Yamada R, Inoue K, Kobayashi K. The Cancer of the Liver Italian Program (CLIP) investigators. A modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003; 29: 735-742
7 Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T, Nakagoe T. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003; 29: 735-742
8 Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Ide N, Sawai T, Yasutake T, Nakagoe T, Nagayasu T, Okuda K, and the Japanese Integrated Staging System Study Group. A Japanese experience. Hepatogastroenterology 2004; 51: 765-770
9 Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, Nagayasu T, Omagari K, Mine M. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Jpn J Clin Oncol 2006; 36: 333-340
10 Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiri M, Ichida T, Arii S, Yamaoka Y. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41: 250-256
11 Figueras J, Jaurrieta E, Valls C, Benascos C, Rafecas A, Xiol X, Fabregat J, Casanovas T, Torras J, Balieillas C, Ibanez L, Moreno P, Casais L. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-1490
12 Sutcliffe R, Maguire D, Portmann B, Rela M, Heaton N. Selection of patients with hepatocellular carcinoma for liver transplantation. Hepatology 2004; 40: 502-507
transplantation. *Br J Surg* 2006; 93: 11-18

14 **Todo S**, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. *Ann Surg* 2004; 240: 451-459; discussion 459-461

15 **Mazzaferro** V, Breglia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334: 693-699

16 **Yao FY**, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl* 2002; 8: 765-774

17 **Liver Cancer Study Group of Japan: Clinical findings.** In: Mukaiuchi M (ed). “The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed.” Tokyo: Kanehara Co., 2003; 6-28

18 **Takasaki T**, Kobayashi S, Suzuki S, Muto H, Marada M, Yamana Y, Nagaoka T. Predicting postoperative hepatic function for hepatectomies. *Int Surg* 1980; 65: 309-313

19 **Miyagawa S**, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. *Am J Surg* 1995; 169: 589-594

20 **Kubota K**, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. *Hepatology* 1997; 26: 1176-1181

21 **Omata M**, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. *Gastroenterology* 2004; 127: S159-S166

22 **Podnos YD**, Henry G, Ortiz JA, Ji P, Cooke J, Cao S, Imagawa DK. Laparoscopic ultrasound with radiofrequency ablation in cirrhotic patients with hepatocellular carcinoma: technique and technical considerations. *Am Surg* 2001; 67: 1181-1184

23 **Kurokohchi K**, Hirai S, Ohgi T, Ono M, Yoshitake A, Ebara K, Kitamura Y, Kasai Y, Maeta T, Kiuchi T, Masaki T, Yoneyama H, Kohi F, Kuriyama S. Thoracoscopic ethanol injection and radiofrequency ablation for the treatment of hepatocellular carcinoma located immediately under the diaphragm. *Int J Oncol* 2006; 29: 375-380

24 **Pugh RN**, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; 60: 646-649

25 **Yanaga K**. Current status of hepatic resection for hepatocellular carcinoma. *J Gastroenterol* 2004; 39: 919-926

26 **Yang W**, Chen MH, Yin SS, Yan K, Gao W, Wang YB, Huo L, Zhang XP, Xin BC. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. *AJR Am J Roentgenol* 2006; 186: S275-S283

27 **Lu MD**, Yin XY, Xie XY, Xu HX, Xu ZF, Liu GJ, Kuang M, Zheng YL. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. *Br J Surg* 2005; 92: 1393-1398

28 **Choi D**, Lim HK, Kim MJ, Lee SH, Kim SH, Lee WJ, Lim JH, Joo JW, Kim YI. Recurrent hepatocellular carcinoma: percutaneous radiofrequency ablation after hepatectomy. *Radiology* 2004; 230: 135-141

29 **Lau WY**, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. *Ann Surg* 2005; 237: 171-179

30 **Bartolozzi** C, Lencioni R. Ethanol injection for the treatment of hepatic tumours. *Eur Radiol* 1996; 6: 692-696

31 **Wakai T**, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz PV, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y, Hatakeyama K. Long-term outcomes of hepatectomy versus percutaneous ablation for treatment of hepatocellular carcinoma < or = 4 cm. *World J Gastroenterol* 2006; 12: 546-552

32 **Shinya S**, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. *Oncology* 2002; 62 Suppl 1: 64-68

33 **Makuuchi M**, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. *World J Gastroenterol* 2006; 12: 828-829

34 **Nakazawa T**, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Sagienni K. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. *AJR Am J Roentgenol* 2007; 188: 480-488

35 **Schindera ST**, Nelson RC, DeLong DM, Clary B. Intrahepatic tumor recurrence after partial hepatectomy: value of percutaneous radiofrequency ablation. *J Vasc Interv Radiol* 2006; 17: 1631-1637

36 **Hong SN**, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joo JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a small hepatocellular carcinoma and well-preserved hepatic function. *J Clin Gastroenterol* 2005; 39: 247-252

37 **Rust C**, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. *Clin Liver Dis* 2001; 5: 161-173

38 **Vivarelli M**, Guglielmi A, Ruzzeneente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. *Ann Surg* 2004; 240: 102-107

39 **Nakahara H**, Itamoto T, Katayama K, Ohdan H, Hino H, Ochi M, Tashiro H, Ashara T. Indication of hepatectomy for cirrhotic patients with hepatocellular carcinoma classified as Child-Pugh class B. *World J Surg* 2005; 29: 734-738

40 **Poon RT**, Fan ST. Hepatocectomy for hepatocellular carcinoma: patient selection and postoperative outcome. *Liver Transpl* 2004; 10: S39-S45

41 **Taura K**, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. *Ann Surg* 2006; **244**: 265-273

42 **Liu YM**, Qin H, Wang CB, Fang XH, Ma QY. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer. *World J Gastroenterol* 2006; 12: 5060-5063

43 **Jiao LR**, Hansen PD, Havlik R, Mitry RR, Pigatelli M, Habib N. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. *Am J Surg* 1999; 177: 303-306

---

**S- Editor** Tsui TY  **E- Editor** Yin DH

www.wjgnet.com